MediciNova ends $30M standby equity line with no fees
MediciNova’s planned termination of its Yorkville standby equity deal takes effect Sept. 8, 2026, with no remaining shares to issue and no termination fees.
Rhea-AI Filing Summary
MediciNova, Inc. (MNOV) has elected to terminate its Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville). The agreement, originally dated July 30, 2025, had allowed MediciNova, on a discretionary basis, to issue and sell up to $30.0 million of common stock to Yorkville. Under this facility, the company sold a total of 175,000 shares at prices between $1.39 and $1.40 per share, receiving aggregate proceeds of $0.2 million. The termination, made via a formal Notice of Termination dated August 31, 2026, will become effective on September 8, 2026. At termination, there were no outstanding borrowings, advance notices, or shares remaining to be issued under the agreement, and no fees are payable by either MediciNova or Yorkville in connection with ending the facility.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 1.02 — Termination of a Material Definitive Agreement
1 item
Item 1.02
Termination of a Material Definitive Agreement
Business
A significant contract was terminated, which may affect business operations or revenue.
Key Figures
Maximum SEPA capacity: $30.0 million
Shares sold under SEPA: 175,000 shares
Sale price range: $1.39–$1.40 per share
+2 more
5 metrics
Maximum SEPA capacity
$30.0 million
Right to issue and sell common stock to Yorkville under the Standby Equity Purchase Agreement
Shares sold under SEPA
175,000 shares
Total MediciNova common shares sold to Yorkville before termination
Sale price range
$1.39–$1.40 per share
Price range for shares sold under the SEPA
Aggregate proceeds from SEPA
$0.2 million
Total cash proceeds MediciNova received from sales under the SEPA
SEPA termination effective date
September 8, 2026
Date the termination of the Standby Equity Purchase Agreement becomes effective
Key Terms
Standby Equity Purchase Agreement, Notice of Termination, advance notices, emerging growth company
4 terms
Standby Equity Purchase Agreement financial
"the Company’s election to terminate the Standby Equity Purchase Agreement"
A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.
Notice of Termination regulatory
"delivered to YA II PN, LTD. (“Yorkville”), a Notice of Termination"
advance notices financial
"there were no outstanding borrowings, advance notices or shares of common stock"
emerging growth company regulatory
"or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did MediciNova (MNOV) announce regarding its Standby Equity Purchase Agreement?
MediciNova delivered a Notice of Termination to YA II PN, LTD. to end its Standby Equity Purchase Agreement. The agreement, which allowed discretionary stock sales to Yorkville, will terminate effective September 8, 2026, with no outstanding borrowings or shares to be issued at termination.
How large was MediciNova’s (MNOV) equity facility with Yorkville and how much was used?
The Standby Equity Purchase Agreement permitted MediciNova to sell up to $30.0 million of common stock to Yorkville. The company utilized only a portion of this, selling 175,000 shares for aggregate proceeds of $0.2 million before terminating the agreement.
When does the termination of MediciNova’s (MNOV) Standby Equity Purchase Agreement become effective?
The termination of MediciNova’s Standby Equity Purchase Agreement with YA II PN, LTD. becomes effective on September 8, 2026. The Notice of Termination was delivered on August 31, 2026, in accordance with the agreement’s termination provisions.
Are there any fees or remaining obligations tied to MediciNova’s (MNOV) SEPA termination?
No. MediciNova states that, at the time of termination, there were no outstanding borrowings, advance notices, or shares to be issued under the SEPA, and no fees are due by either MediciNova or YA II PN, LTD. in connection with the termination.
AI-generated analysis. How Rhea-AI works. Not financial advice.
